What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue World Journal of Urology Année : 2022

What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?

(1, 2, 3) , (4) , (5) , , (3) , (6) , (7, 8) , (9) , (10) , (11) , (12) , (13) , (14) , (14) , (4) , (15, 3)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Guilhem Roubaud
  • Fonction : Auteur
  • PersonId : 975634
Mathieu Gauthé
  • Fonction : Auteur
  • PersonId : 1010400
Eric Barret
  • Fonction : Auteur
  • PersonId : 1116883
Gilles Créhange
  • Fonction : Auteur
  • PersonId : 1110793
Romain Mathieu
  • Fonction : Auteur
  • PersonId : 1024638
Morgan Rouprêt
  • Fonction : Auteur
  • PersonId : 1003501
Raphaële Renard-Penna
  • Fonction : Auteur
  • PersonId : 1110794
Paul Sargos
  • Fonction : Auteur
  • PersonId : 1042270

Résumé

PURPOSE: To review current evidence regarding the management of de novo, oligometastatic, castration-sensitive prostate cancer (PCa). METHODS: A literature search was conducted on PubMed/Medline and a narrative synthesis of the evidence was performed in August 2022. RESULTS: Oligometastatic disease is an intermediate state between localized and aggressive metastatic PCa defined by ≤ 3-5 metastatic lesions, although this definition remains controversial. Conventional imaging has limited accuracy in detecting metastatic lesions, and the implementation of molecular imaging could pave the way for a more personalized treatment strategy. However, oncological data supporting this strategy are needed. Radiotherapy to the primary tumor should be considered standard treatment for oligometastatic PCa (omPCa). However, it remains to be seen whether local therapy still has an additional survival benefit in patients with de novo omPCa when treated with the most modern systemic therapy combinations. There is insufficient evidence to recommend cytoreductive radical prostatectomy as local therapy; or stereotactic body radiotherapy as metastasis-directed therapy in patients with omPCa. Current data support the use of intensified systemic therapy with androgen deprivation therapy (ADT) and next-generation hormone therapies (NHT) for patients with de novo omPCa. Docetaxel has not demonstrated benefit in low volume disease. There are insufficient data to support the use of triple therapy (i.e., ADT + NHT + Docetaxel) in low volume disease. CONCLUSION: The present review discusses current data in de novo, omPCa regarding its definition, the increasing role of molecular imaging, the place of local and metastasis-directed therapies, and the intensification of systemic therapies.
Fichier non déposé

Dates et versions

hal-03923304 , version 1 (04-01-2023)

Identifiants

Citer

Michael Baboudjian, Guilhem Roubaud, Gaëlle Fromont, Mathieu Gauthé, Jean Baptiste Beauval, et al.. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?. World Journal of Urology, 2022, ⟨10.1007/s00345-022-04239-1⟩. ⟨hal-03923304⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More